PMID- 35069083
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220430
IS  - 1661-7649 (Print)
IS  - 1661-7657 (Electronic)
IS  - 1661-7649 (Linking)
VI  - 15
IP  - 4
DP  - 2021 Dec
TI  - Patients and physician satisfaction of Degarelix in androgen deprivation therapy 
      for advanced hormone-dependent prostate cancer in the Netherlands.
PG  - 204-208
LID - 10.1097/CU9.0000000000000029 [doi]
AB  - BACKGROUND: To explore the effectiveness and safety of the gonadotropin-releasing 
      hormone antagonist, Degarelix, for the treatment of advanced hormone-dependent 
      prostate cancer (PCa) in a real-world setting. METHODS: In this noninterventional 
      study, patients with advanced hormone-dependent PCa were included. Primary 
      endpoints were progression-free survival (PFS) failure defined as either 
      prostate-specific antigen failure, additional therapy related to PCa, or death. 
      Secondary endpoints included patient and physician satisfaction scores, urinary 
      symptoms, and adverse events (AEs). RESULTS: Of 274 patients with PCa, 271 
      received at least 1 dose of Degarelix. At a median follow-up of 12.2 
      (interquartile range 6.2-22.0) months, 148 patients (60.2%) had PFS failure. 
      Thirty-five patients (13%) withdrew from the study due to AEs, 23 patients (8.4%) 
      died, and 36 patients (13%) completed 3 years' follow-up. Urinary symptoms 
      significantly decreased over time. In the safety population, 87.8% of patients 
      reported AEs, with injection-site reactions commonly reported. The majority of 
      physicians and patients considered the therapy satisfactory and well tolerated. 
      CONCLUSIONS: In this observational study, Degarelix treatment was well accepted 
      by men with advanced hormone-dependent PCa. Compared with phase III studies, a 
      higher proportion of patients had PFS failure, possibly due to the inclusion of 
      men with more advanced disease in the current study, and more men reported AEs.
CI  - Copyright (c) 2021 The Authors. Published by Wolters Kluwer Health, Inc.
FAU - Roshani, Hossain
AU  - Roshani H
AD  - Department of Urology, Haga Ziekenhuis, The Hague, The Netherlands.
FAU - Roos, Erik P M
AU  - Roos EPM
AD  - Department of Urology, Antonius Ziekenhuis, Sneek, The Netherlands.
FAU - Elzevier, Henk W
AU  - Elzevier HW
AD  - Department of Urology, Leiden University Medical Center, Leiden, The Netherlands.
FAU - van de Beek, Cees
AU  - van de Beek C
AD  - Department of Urology, Maastricht University Medical Center, Maastricht, The 
      Netherlands.
FAU - van Winkel, Peter
AU  - van Winkel P
AD  - Medical Affairs, Ferring B.V. Hoofddorp, The Netherlands.
FAU - Pelger, Rob C M
AU  - Pelger RCM
AD  - Department of Urology, Leiden University Medical Center, Leiden, The Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20210625
PL  - United States
TA  - Curr Urol
JT  - Current urology
JID - 101471188
PMC - PMC8772641
OTO - NOTNLM
OT  - Androgen antagonists
OT  - Clinical trials
OT  - Degarelix
OT  - Prostate-specific antigen
OT  - Prostatic neoplasms
COIS- H Roshani: no conflict of interest. EPM Roos, HW Elzevier, C van de Beek, and RCM 
      Pelger: received study fees from Ferring. P van Winkel: full-time employee of 
      Ferring B.V., The Netherlands.
EDAT- 2022/01/25 06:00
MHDA- 2022/01/25 06:01
PMCR- 2021/12/01
CRDT- 2022/01/24 08:47
PHST- 2019/12/04 00:00 [received]
PHST- 2020/03/11 00:00 [accepted]
PHST- 2022/01/24 08:47 [entrez]
PHST- 2022/01/25 06:00 [pubmed]
PHST- 2022/01/25 06:01 [medline]
PHST- 2021/12/01 00:00 [pmc-release]
AID - Curr-Urol-21-0103 [pii]
AID - 10.1097/CU9.0000000000000029 [doi]
PST - ppublish
SO  - Curr Urol. 2021 Dec;15(4):204-208. doi: 10.1097/CU9.0000000000000029. Epub 2021 
      Jun 25.